25 XP   0   0   10

AstraZeneca PLC
Buy, Hold or Sell?

Let's analyse Astrazeneca together

PenkeI guess you are interested in AstraZeneca PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of AstraZeneca PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about AstraZeneca PLC

I send you an email if I find something interesting about AstraZeneca PLC.

Quick analysis of Astrazeneca (30 sec.)










What can you expect buying and holding a share of Astrazeneca? (30 sec.)

How much money do you get?

How much money do you get?
kr2.87
When do you have the money?
1 year
How often do you get paid?
82.5%

What is your share worth?

Current worth
kr268.90
Expected worth in 1 year
kr284.81
How sure are you?
87.5%

+ What do you gain per year?

Total Gains per Share
kr46.48
Return On Investment
3.2%

For what price can you sell your share?

Current Price per Share
kr1,452.50
Expected price per share
kr1,414 - kr1,521
How sure are you?
50%

1. Valuation of Astrazeneca (5 min.)




Live pricePrice per Share (EOD)

kr1,452.50

Intrinsic Value Per Share

kr130.68 - kr416.53

Total Value Per Share

kr399.58 - kr685.44

2. Growth of Astrazeneca (5 min.)




Is Astrazeneca growing?

Current yearPrevious yearGrowGrow %
How rich?$39.1b$36.1b$1.2b3.4%

How much money is Astrazeneca making?

Current yearPrevious yearGrowGrow %
Making money$1.4b$822.1m$667.3m44.8%
Net Profit Margin13.1%7.4%--

How much money comes from the company's main activities?

3. Financial Health of Astrazeneca (5 min.)




What can you expect buying and holding a share of Astrazeneca? (5 min.)

Welcome investor! Astrazeneca's management wants to use your money to grow the business. In return you get a share of Astrazeneca.

What can you expect buying and holding a share of Astrazeneca?

First you should know what it really means to hold a share of Astrazeneca. And how you can make/lose money.

Speculation

The Price per Share of Astrazeneca is kr1,453. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Astrazeneca.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Astrazeneca, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr268.90. Based on the TTM, the Book Value Change Per Share is kr3.98 per quarter. Based on the YOY, the Book Value Change Per Share is kr-4.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr7.64 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Astrazeneca.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.620.0%0.960.1%0.530.0%0.450.0%0.430.0%
Usd Book Value Change Per Share1.410.1%0.370.0%-0.390.0%0.810.1%0.260.0%
Usd Dividend Per Share0.000.0%0.720.0%1.420.1%1.160.1%0.980.1%
Usd Total Gains Per Share1.410.1%1.090.1%1.020.1%1.970.1%1.230.1%
Usd Price Per Share127.23-137.13-123.12-103.98-78.03-
Price to Earnings Ratio51.34-37.91-84.95-54.90--111.66-
Price-to-Total Gains Ratio90.41-132.20-1,206.69-639.27-356.26-
Price to Book Ratio5.03-5.72-5.30-7.24-6.09-
Price-to-Total Gains Ratio90.41-132.20-1,206.69-639.27-356.26-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share136.535
Number of shares7
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.721.16
Usd Book Value Change Per Share0.370.81
Usd Total Gains Per Share1.091.97
Gains per Quarter (7 shares)7.6513.77
Gains per Year (7 shares)30.5855.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1201021322345
24021526545100
36031839768155
4804211413091210
510152145162113265
612163176194136320
714173207227159375
816184238259182430
918194269291204485
10201105300324227540

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%18.02.00.090.0%36.04.00.090.0%92.06.00.093.9%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%9.011.00.045.0%17.023.00.042.5%46.039.013.046.9%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%19.00.01.095.0%33.00.07.082.5%58.00.040.059.2%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%35.05.00.087.5%76.012.010.077.6%

Fundamentals of Astrazeneca

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Fundamental data was last updated by Penke on 2024-03-20 11:01:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of AstraZeneca PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Astrazeneca earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Astrazeneca to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 8.0% means that kr0.08 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AstraZeneca PLC:

  • The MRQ is 8.0%. The company is making a profit. +1
  • The TTM is 13.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ8.0%TTM13.1%-5.1%
TTM13.1%YOY7.4%+5.7%
TTM13.1%5Y8.0%+5.1%
5Y8.0%10Y9.4%-1.4%
1.1.2. Return on Assets

Shows how efficient Astrazeneca is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Astrazeneca to the Drug Manufacturers - General industry mean.
  • 0.9% Return on Assets means that Astrazeneca generated kr0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AstraZeneca PLC:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.9%TTM1.5%-0.6%
TTM1.5%YOY0.9%+0.7%
TTM1.5%5Y0.9%+0.6%
5Y0.9%10Y1.0%-0.1%
1.1.3. Return on Equity

Shows how efficient Astrazeneca is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Astrazeneca to the Drug Manufacturers - General industry mean.
  • 2.5% Return on Equity means Astrazeneca generated kr0.02 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AstraZeneca PLC:

  • The MRQ is 2.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 4.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.5%TTM4.0%-1.6%
TTM4.0%YOY2.3%+1.7%
TTM4.0%5Y3.6%+0.5%
5Y3.6%10Y3.9%-0.3%

1.2. Operating Efficiency of AstraZeneca PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Astrazeneca is operating .

  • Measures how much profit Astrazeneca makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Astrazeneca to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 16.9% means the company generated kr0.17  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AstraZeneca PLC:

  • The MRQ is 16.9%. The company is operating efficient. +1
  • The TTM is 17.3%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ16.9%TTM17.3%-0.3%
TTM17.3%YOY5.2%+12.0%
TTM17.3%5Y12.0%+5.3%
5Y12.0%10Y13.7%-1.7%
1.2.2. Operating Ratio

Measures how efficient Astrazeneca is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.83 means that the operating costs are kr0.83 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of AstraZeneca PLC:

  • The MRQ is 0.833. The company is less efficient in keeping operating costs low.
  • The TTM is 0.809. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.833TTM0.809+0.024
TTM0.809YOY0.912-0.103
TTM0.8095Y0.881-0.072
5Y0.88110Y0.886-0.005

1.3. Liquidity of AstraZeneca PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Astrazeneca is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 0.82 means the company has kr0.82 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of AstraZeneca PLC:

  • The MRQ is 0.820. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.842. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.820TTM0.842-0.022
TTM0.842YOY0.907-0.065
TTM0.8425Y0.918-0.075
5Y0.91810Y0.897+0.021
1.3.2. Quick Ratio

Measures if Astrazeneca is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Astrazeneca to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.47 means the company can pay off kr0.47 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AstraZeneca PLC:

  • The MRQ is 0.468. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.595. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.468TTM0.595-0.127
TTM0.595YOY0.652-0.057
TTM0.5955Y0.676-0.081
5Y0.67610Y0.587+0.090

1.4. Solvency of AstraZeneca PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Astrazeneca assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Astrazeneca to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.61 means that Astrazeneca assets are financed with 61.3% credit (debt) and the remaining percentage (100% - 61.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AstraZeneca PLC:

  • The MRQ is 0.613. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.617. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.613TTM0.617-0.004
TTM0.617YOY0.627-0.010
TTM0.6175Y0.700-0.083
5Y0.70010Y0.710-0.010
1.4.2. Debt to Equity Ratio

Measures if Astrazeneca is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Astrazeneca to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 158.3% means that company has kr1.58 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AstraZeneca PLC:

  • The MRQ is 1.583. The company is just able to pay all its debts with equity.
  • The TTM is 1.612. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.583TTM1.612-0.029
TTM1.612YOY1.683-0.071
TTM1.6125Y2.727-1.115
5Y2.72710Y2.826-0.099

2. Market Valuation of AstraZeneca PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Astrazeneca generates.

  • Above 15 is considered overpriced but always compare Astrazeneca to the Drug Manufacturers - General industry mean.
  • A PE ratio of 51.34 means the investor is paying kr51.34 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AstraZeneca PLC:

  • The EOD is 55.093. Based on the earnings, the company is expensive. -2
  • The MRQ is 51.338. Based on the earnings, the company is expensive. -2
  • The TTM is 37.907. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD55.093MRQ51.338+3.755
MRQ51.338TTM37.907+13.431
TTM37.907YOY84.951-47.044
TTM37.9075Y54.904-16.997
5Y54.90410Y-111.656+166.560
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AstraZeneca PLC:

  • The EOD is 36.883. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 34.369. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 34.135. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD36.883MRQ34.369+2.514
MRQ34.369TTM34.135+0.234
TTM34.135YOY34.688-0.553
TTM34.1355Y35.156-1.021
5Y35.15610Y30.358+4.798
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Astrazeneca is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 5.03 means the investor is paying kr5.03 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of AstraZeneca PLC:

  • The EOD is 5.402. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.033. Based on the equity, the company is overpriced. -1
  • The TTM is 5.719. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.402MRQ5.033+0.368
MRQ5.033TTM5.719-0.685
TTM5.719YOY5.302+0.417
TTM5.7195Y7.244-1.525
5Y7.24410Y6.090+1.154
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of AstraZeneca PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--14.9583.977+276%-4.185+128%8.624+73%2.731+448%
Book Value Per Share--268.903255.612+5%246.976+9%175.983+53%145.851+84%
Current Ratio--0.8200.842-3%0.907-10%0.918-11%0.897-9%
Debt To Asset Ratio--0.6130.617-1%0.627-2%0.700-12%0.710-14%
Debt To Equity Ratio--1.5831.612-2%1.683-6%2.727-42%2.826-44%
Dividend Per Share--0.0147.643-100%15.053-100%12.302-100%10.380-100%
Eps--6.59110.168-35%5.613+17%4.750+39%4.557+45%
Free Cash Flow Per Share--9.84511.216-12%12.379-20%6.938+42%5.165+91%
Free Cash Flow To Equity Per Share--7.8480.012+63639%0.699+1023%2.252+248%1.426+450%
Gross Profit Margin---17.571-5.825-67%-7.382-58%-4.610-74%22.539-178%
Intrinsic Value_10Y_max--416.535--------
Intrinsic Value_10Y_min--130.682--------
Intrinsic Value_1Y_max--40.370--------
Intrinsic Value_1Y_min--19.499--------
Intrinsic Value_3Y_max--122.339--------
Intrinsic Value_3Y_min--53.386--------
Intrinsic Value_5Y_max--205.568--------
Intrinsic Value_5Y_min--81.316--------
Market Cap2251680094720.000+7%2098209299968.0002272532324992.000-8%2039492837488.000+3%1718849577714.560+22%1288809719002.560+63%
Net Profit Margin--0.0800.131-39%0.074+8%0.080-1%0.094-15%
Operating Margin--0.1690.173-2%0.052+222%0.120+41%0.137+24%
Operating Ratio--0.8330.809+3%0.912-9%0.881-5%0.886-6%
Pb Ratio5.402+7%5.0335.719-12%5.302-5%7.244-31%6.090-17%
Pe Ratio55.093+7%51.33837.907+35%84.951-40%54.904-6%-111.656+317%
Price Per Share1452.500+7%1353.5001458.875-7%1309.750+3%1106.195+22%830.083+63%
Price To Free Cash Flow Ratio36.883+7%34.36934.135+1%34.688-1%35.156-2%30.358+13%
Price To Total Gains Ratio97.019+7%90.406132.200-32%1206.688-93%639.267-86%356.265-75%
Quick Ratio--0.4680.595-21%0.652-28%0.676-31%0.587-20%
Return On Assets--0.0090.015-38%0.009+11%0.009+4%0.010-3%
Return On Equity--0.0250.040-39%0.023+7%0.036-31%0.039-37%
Total Gains Per Share--14.97111.620+29%10.869+38%20.926-28%13.111+14%
Usd Book Value--39184415853.20037421087125.700+5%36147488561.100+8%25710533411.190+52%21286529222.055+84%
Usd Book Value Change Per Share--1.4060.374+276%-0.393+128%0.811+73%0.257+448%
Usd Book Value Per Share--25.27724.028+5%23.216+9%16.542+53%13.710+84%
Usd Dividend Per Share--0.0010.718-100%1.415-100%1.156-100%0.976-100%
Usd Eps--0.6200.956-35%0.528+17%0.447+39%0.428+45%
Usd Free Cash Flow--1434674266.8001642521950.850-13%1810100709.350-21%1013926524.190+41%754029377.985+90%
Usd Free Cash Flow Per Share--0.9251.054-12%1.164-20%0.652+42%0.485+91%
Usd Free Cash Flow To Equity Per Share--0.7380.001+63639%0.066+1023%0.212+248%0.134+450%
Usd Market Cap211657928903.680+7%197231674196.992213618038549.248-8%191712326723.872+3%161571860305.169+22%121148113586.241+63%
Usd Price Per Share136.535+7%127.229137.134-7%123.117+3%103.982+22%78.028+63%
Usd Profit--960451392.0001489450010.250-36%822136386.850+17%694576436.350+38%665262659.490+44%
Usd Revenue--12029653684.80011458135083.050+5%11092713342.500+8%8933148392.290+35%7426965517.945+62%
Usd Total Gains Per Share--1.4071.092+29%1.022+38%1.967-28%1.232+14%
 EOD+4 -4MRQTTM+14 -22YOY+26 -105Y+25 -1110Y+24 -12

3.2. Fundamental Score

Let's check the fundamental score of AstraZeneca PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1555.093
Price to Book Ratio (EOD)Between0-15.402
Net Profit Margin (MRQ)Greater than00.080
Operating Margin (MRQ)Greater than00.169
Quick Ratio (MRQ)Greater than10.468
Current Ratio (MRQ)Greater than10.820
Debt to Asset Ratio (MRQ)Less than10.613
Debt to Equity Ratio (MRQ)Less than11.583
Return on Equity (MRQ)Greater than0.150.025
Return on Assets (MRQ)Greater than0.050.009
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of AstraZeneca PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5072.221
Ma 20Greater thanMa 501,378.525
Ma 50Greater thanMa 1001,358.280
Ma 100Greater thanMa 2001,350.907
OpenGreater thanClose1,450.000
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Retained Earnings  -6,109,254-13,314,768-19,424,02316,933,490-2,490,532-2,128,660-4,619,19220,605,42915,986,237
Minority Interest  -10,6430-10,643-10,643-21,287-21,287-42,57353,21710,643



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets101,119,000
Total Liabilities61,953,000
Total Stockholder Equity39,143,000
 As reported
Total Liabilities 61,953,000
Total Stockholder Equity+ 39,143,000
Total Assets = 101,119,000

Assets

Total Assets101,119,000
Total Current Assets25,054,000
Long-term Assets76,065,000
Total Current Assets
Cash And Cash Equivalents 5,840,000
Short-term Investments 20,000
Net Receivables 8,407,000
Inventory 5,424,000
Total Current Assets  (as reported)25,054,000
Total Current Assets  (calculated)19,691,000
+/- 5,363,000
Long-term Assets
Property Plant Equipment 10,502,000
Goodwill 20,048,000
Intangible Assets 38,089,000
Long-term Assets Other 1,051,000
Long-term Assets  (as reported)76,065,000
Long-term Assets  (calculated)69,690,000
+/- 6,375,000

Liabilities & Shareholders' Equity

Total Current Liabilities30,542,000
Long-term Liabilities31,411,000
Total Stockholder Equity39,143,000
Total Current Liabilities
Short-term Debt 5,400,000
Short Long Term Debt 5,129,000
Accounts payable 3,267,000
Other Current Liabilities 21,875,000
Total Current Liabilities  (as reported)30,542,000
Total Current Liabilities  (calculated)35,671,000
+/- 5,129,000
Long-term Liabilities
Long term Debt 22,365,000
Capital Lease Obligations 1,128,000
Long-term Liabilities  (as reported)31,411,000
Long-term Liabilities  (calculated)23,493,000
+/- 7,918,000
Total Stockholder Equity
Common Stock388,000
Retained Earnings 1,502,000
Other Stockholders Equity 37,253,000
Total Stockholder Equity (as reported)39,143,000
Total Stockholder Equity (calculated)39,143,000
+/-0
Other
Capital Stock388,000
Cash and Short Term Investments 5,860,000
Common Stock Shares Outstanding 1,550,163
Liabilities and Stockholders Equity 101,119,000
Net Debt 22,782,000
Net Invested Capital 66,637,000
Net Working Capital -5,488,000
Property Plant and Equipment Gross 19,101,000
Short Long Term Debt Total 28,622,000



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-12-311994-09-301994-06-301994-03-311993-12-311993-09-301993-06-301993-03-31
> Total Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,576,000
22,532,081
22,207,711
23,054,000
23,573,000
23,785,000
24,343,000
24,471,000
25,616,000
24,840,000
24,884,000
24,527,000
24,840,000
29,932,000
28,459,000
28,122,000
29,932,000
29,565,000
47,600,000
45,950,000
47,957,000
48,458,000
50,202,000
48,204,000
46,784,000
46,515,000
50,200,000
51,899,000
54,920,000
54,075,000
54,647,000
56,390,000
56,127,000
54,534,000
53,406,000
52,576,000
52,830,000
50,763,000
51,390,000
52,448,000
53,534,000
52,329,000
53,987,000
54,121,000
55,899,000
59,390,000
58,539,000
56,164,000
58,595,000
53,701,000
55,169,000
54,118,000
60,124,000
64,323,000
64,419,000
63,222,000
62,526,000
60,959,000
65,119,000
64,587,000
63,354,000
63,281,000
61,344,000
61,443,000
60,651,000
61,055,000
61,889,000
58,906,000
61,377,000
57,211,000
59,929,000
64,112,000
66,729,000
64,926,000
73,641,000
107,221,000
105,363,000
100,273,000
96,579,000
94,185,000
96,483,000
96,687,000
96,543,000
96,086,000
101,119,000
101,119,00096,086,00096,543,00096,687,00096,483,00094,185,00096,579,000100,273,000105,363,000107,221,00073,641,00064,926,00066,729,00064,112,00059,929,00057,211,00061,377,00058,906,00061,889,00061,055,00060,651,00061,443,00061,344,00063,281,00063,354,00064,587,00065,119,00060,959,00062,526,00063,222,00064,419,00064,323,00060,124,00054,118,00055,169,00053,701,00058,595,00056,164,00058,539,00059,390,00055,899,00054,121,00053,987,00052,329,00053,534,00052,448,00051,390,00050,763,00052,830,00052,576,00053,406,00054,534,00056,127,00056,390,00054,647,00054,075,00054,920,00051,899,00050,200,00046,515,00046,784,00048,204,00050,202,00048,458,00047,957,00045,950,00047,600,00029,565,00029,932,00028,122,00028,459,00029,932,00024,840,00024,527,00024,884,00024,840,00025,616,00024,471,00024,343,00023,785,00023,573,00023,054,00022,207,71122,532,08121,576,000000000000000000000000000000000000000000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,126,000
12,950,313
12,265,081
12,996,000
12,933,000
13,261,000
11,911,000
12,253,000
14,440,000
13,770,000
13,438,000
13,095,000
13,770,000
16,936,000
15,051,000
14,433,000
16,936,000
16,286,000
16,078,000
14,691,000
17,082,000
14,452,000
16,476,000
15,570,000
16,152,000
15,852,000
19,126,000
20,540,000
23,760,000
22,347,000
23,376,000
24,569,000
25,131,000
23,467,000
22,691,000
22,467,000
23,506,000
21,560,000
19,777,000
18,029,000
19,048,000
18,344,000
19,394,000
18,792,000
20,335,000
16,542,000
16,204,000
15,072,000
16,697,000
12,691,000
13,812,000
13,199,000
16,007,000
12,769,000
13,320,000
12,866,000
13,262,000
11,637,000
14,298,000
13,634,000
13,150,000
13,182,000
12,449,000
13,108,000
15,591,000
13,649,000
15,219,000
13,520,000
15,563,000
12,822,000
14,930,000
18,166,000
19,544,000
18,735,000
27,274,000
26,691,000
26,244,000
22,647,000
20,917,000
20,224,000
22,593,000
22,266,000
22,839,000
22,501,000
25,054,000
25,054,00022,501,00022,839,00022,266,00022,593,00020,224,00020,917,00022,647,00026,244,00026,691,00027,274,00018,735,00019,544,00018,166,00014,930,00012,822,00015,563,00013,520,00015,219,00013,649,00015,591,00013,108,00012,449,00013,182,00013,150,00013,634,00014,298,00011,637,00013,262,00012,866,00013,320,00012,769,00016,007,00013,199,00013,812,00012,691,00016,697,00015,072,00016,204,00016,542,00020,335,00018,792,00019,394,00018,344,00019,048,00018,029,00019,777,00021,560,00023,506,00022,467,00022,691,00023,467,00025,131,00024,569,00023,376,00022,347,00023,760,00020,540,00019,126,00015,852,00016,152,00015,570,00016,476,00014,452,00017,082,00014,691,00016,078,00016,286,00016,936,00014,433,00015,051,00016,936,00013,770,00013,095,00013,438,00013,770,00014,440,00012,253,00011,911,00013,261,00012,933,00012,996,00012,265,08112,950,31312,126,000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
726,000
0
3,998,110
0
733,000
814,000
1,499,000
1,020,000
1,055,000
4,979,000
5,451,000
4,400,000
545,000
7,103,000
6,076,000
5,756,000
7,103,000
5,567,000
4,951,000
3,428,000
5,867,000
2,920,000
4,340,000
3,541,000
4,286,000
4,441,000
7,195,000
7,794,000
9,918,000
7,366,000
9,088,000
10,010,000
11,068,000
9,582,000
9,613,000
9,860,000
7,571,000
6,332,000
7,641,000
6,017,000
7,701,000
7,234,000
8,252,000
7,453,000
9,098,000
4,379,000
4,958,000
5,146,000
6,246,000
3,192,000
3,967,000
4,081,000
6,130,000
3,428,000
3,915,000
3,090,000
4,927,000
3,129,000
5,239,000
4,036,000
3,231,000
3,005,000
2,978,000
3,420,000
4,745,000
4,136,000
5,428,000
3,967,000
5,369,000
3,413,000
5,673,000
8,072,000
7,832,000
7,636,000
15,567,000
7,067,000
6,329,000
5,762,000
4,817,000
4,458,000
6,166,000
6,232,000
5,664,000
4,871,000
5,840,000
5,840,0004,871,0005,664,0006,232,0006,166,0004,458,0004,817,0005,762,0006,329,0007,067,00015,567,0007,636,0007,832,0008,072,0005,673,0003,413,0005,369,0003,967,0005,428,0004,136,0004,745,0003,420,0002,978,0003,005,0003,231,0004,036,0005,239,0003,129,0004,927,0003,090,0003,915,0003,428,0006,130,0004,081,0003,967,0003,192,0006,246,0005,146,0004,958,0004,379,0009,098,0007,453,0008,252,0007,234,0007,701,0006,017,0007,641,0006,332,0007,571,0009,860,0009,613,0009,582,00011,068,00010,010,0009,088,0007,366,0009,918,0007,794,0007,195,0004,441,0004,286,0003,541,0004,340,0002,920,0005,867,0003,428,0004,951,0005,567,0007,103,0005,756,0006,076,0007,103,000545,0004,400,0005,451,0004,979,0001,055,0001,020,0001,499,000814,000733,00003,998,1100726,000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,962,000
0
0
0
3,218,000
0
2,573,000
3,167,000
4,091,000
1,624,000
398,000
1,242,000
6,058,000
657,000
1,020,000
413,000
581,000
849,000
360,000
102,000
91,000
55,000
58,000
55,000
388,000
49,000
42,000
40,000
1,508,000
2,030,000
1,964,000
1,517,000
1,482,000
1,199,000
679,000
924,000
4,248,000
3,637,000
1,555,000
799,000
823,000
795,000
839,000
864,000
796,000
777,000
819,000
804,000
795,000
493,000
531,000
496,000
613,000
671,000
731,000
909,000
884,000
530,000
998,000
1,175,000
1,230,000
866,000
799,000
808,000
809,000
822,000
819,000
813,000
811,000
752,000
442,000
374,000
118,000
129,000
62,000
82,000
69,000
61,000
70,000
440,000
239,000
230,000
148,000
244,000
20,000
20,000244,000148,000230,000239,000440,00070,00061,00069,00082,00062,000129,000118,000374,000442,000752,000811,000813,000819,000822,000809,000808,000799,000866,0001,230,0001,175,000998,000530,000884,000909,000731,000671,000613,000496,000531,000493,000795,000804,000819,000777,000796,000864,000839,000795,000823,000799,0001,555,0003,637,0004,248,000924,000679,0001,199,0001,482,0001,517,0001,964,0002,030,0001,508,00040,00042,00049,000388,00055,00058,00055,00091,000102,000360,000849,000581,000413,0001,020,000657,0006,058,0001,242,000398,0001,624,0004,091,0003,167,0002,573,00003,218,0000003,962,000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,313,000
5,134,000
5,261,000
5,242,000
6,007,000
5,521,000
5,819,000
5,594,000
5,289,000
5,319,000
5,279,000
5,181,000
5,342,000
5,237,000
6,000,000
5,651,000
6,628,000
6,842,000
8,854,000
8,795,000
9,050,000
9,721,000
10,166,000
10,521,000
10,289,000
11,092,000
11,300,000
8,407,000
8,407,00011,300,00011,092,00010,289,00010,521,00010,166,0009,721,0009,050,0008,795,0008,854,0006,842,0006,628,0005,651,0006,000,0005,237,0005,342,0005,181,0005,279,0005,319,0005,289,0005,594,0005,819,0005,521,0006,007,0005,242,0005,261,0005,134,0005,313,000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,845,000
12,950,313
5,494,267
12,996,000
5,960,000
9,348,000
4,701,000
4,986,000
6,274,000
4,961,000
4,926,000
4,960,000
4,961,000
6,926,000
5,744,000
6,055,000
7,002,000
7,576,000
8,204,000
8,603,000
9,005,000
9,308,000
9,809,000
9,891,000
9,842,000
9,660,000
10,023,000
10,808,000
10,584,000
11,171,000
10,635,000
11,232,000
10,899,000
10,789,000
10,378,000
9,728,000
9,835,000
9,551,000
8,542,000
9,123,000
8,463,000
8,276,000
8,214,000
8,400,000
8,532,000
9,223,000
8,178,000
7,165,000
7,696,000
7,038,000
7,116,000
6,429,000
7,121,000
6,326,000
6,252,000
6,447,000
5,117,000
5,326,000
5,160,000
5,261,000
5,654,000
6,028,000
5,554,000
5,853,000
7,147,000
5,641,000
5,775,000
5,611,000
6,190,000
5,534,000
5,253,000
6,037,000
7,570,000
6,692,000
6,883,000
9,014,000
10,863,000
9,200,000
89,000
82,000
11,489,000
548,000
884,000
794,000
0
0794,000884,000548,00011,489,00082,00089,0009,200,00010,863,0009,014,0006,883,0006,692,0007,570,0006,037,0005,253,0005,534,0006,190,0005,611,0005,775,0005,641,0007,147,0005,853,0005,554,0006,028,0005,654,0005,261,0005,160,0005,326,0005,117,0006,447,0006,252,0006,326,0007,121,0006,429,0007,116,0007,038,0007,696,0007,165,0008,178,0009,223,0008,532,0008,400,0008,214,0008,276,0008,463,0009,123,0008,542,0009,551,0009,835,0009,728,00010,378,00010,789,00010,899,00011,232,00010,635,00011,171,00010,584,00010,808,00010,023,0009,660,0009,842,0009,891,0009,809,0009,308,0009,005,0008,603,0008,204,0007,576,0007,002,0006,055,0005,744,0006,926,0004,961,0004,960,0004,926,0004,961,0006,274,0004,986,0004,701,0009,348,0005,960,00012,996,0005,494,26712,950,3134,845,000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,450,000
9,581,768
9,942,629
10,058,000
10,640,000
10,524,000
12,432,000
12,218,000
11,176,000
11,070,000
11,446,000
11,432,000
11,070,000
12,996,000
13,408,000
13,689,000
12,996,000
13,279,000
31,522,000
31,259,000
30,875,000
34,006,000
33,726,000
32,634,000
30,632,000
30,663,000
31,074,000
31,359,000
31,160,000
31,728,000
31,271,000
31,821,000
30,996,000
31,067,000
30,715,000
30,109,000
29,324,000
29,203,000
31,613,000
34,419,000
34,486,000
33,985,000
34,593,000
35,329,000
35,564,000
42,848,000
42,335,000
41,092,000
41,898,000
41,010,000
41,357,000
40,919,000
44,117,000
51,554,000
51,099,000
50,356,000
49,264,000
49,322,000
50,821,000
50,953,000
50,204,000
50,099,000
48,895,000
48,335,000
45,060,000
47,406,000
46,670,000
45,386,000
45,814,000
44,389,000
44,999,000
45,946,000
47,185,000
46,191,000
46,367,000
80,530,000
79,119,000
77,626,000
75,662,000
73,961,000
73,890,000
74,421,000
73,704,000
73,585,000
76,065,000
76,065,00073,585,00073,704,00074,421,00073,890,00073,961,00075,662,00077,626,00079,119,00080,530,00046,367,00046,191,00047,185,00045,946,00044,999,00044,389,00045,814,00045,386,00046,670,00047,406,00045,060,00048,335,00048,895,00050,099,00050,204,00050,953,00050,821,00049,322,00049,264,00050,356,00051,099,00051,554,00044,117,00040,919,00041,357,00041,010,00041,898,00041,092,00042,335,00042,848,00035,564,00035,329,00034,593,00033,985,00034,486,00034,419,00031,613,00029,203,00029,324,00030,109,00030,715,00031,067,00030,996,00031,821,00031,271,00031,728,00031,160,00031,359,00031,074,00030,663,00030,632,00032,634,00033,726,00034,006,00030,875,00031,259,00031,522,00013,279,00012,996,00013,689,00013,408,00012,996,00011,070,00011,432,00011,446,00011,070,00011,176,00012,218,00012,432,00010,524,00010,640,00010,058,0009,942,6299,581,7689,450,000000000000000000000000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,597,000
9,581,768
7,024,520
10,058,000
7,536,000
7,556,000
7,537,000
9,177,000
8,083,000
6,985,000
7,355,000
7,262,000
6,985,000
7,453,000
7,269,000
7,297,000
7,453,000
7,420,000
8,161,000
8,316,000
8,298,000
8,486,000
8,479,000
7,830,000
7,043,000
6,820,000
7,262,000
7,363,000
7,307,000
7,067,000
6,824,000
7,096,000
6,957,000
7,062,000
6,832,000
6,526,000
6,425,000
6,335,000
6,047,000
6,094,000
6,089,000
5,882,000
5,665,000
5,728,000
5,818,000
6,173,000
6,150,000
5,989,000
6,010,000
5,913,000
6,134,000
6,205,000
6,413,000
6,560,000
6,613,000
6,690,000
6,848,000
6,954,000
7,079,000
7,329,000
7,615,000
7,721,000
7,514,000
7,591,000
7,421,000
8,153,000
8,144,000
8,007,000
8,335,000
7,991,000
8,109,000
8,360,000
8,917,000
8,849,000
9,031,000
10,162,000
10,171,000
10,015,000
9,627,000
9,227,000
9,449,000
9,599,000
9,624,000
9,700,000
10,502,000
10,502,0009,700,0009,624,0009,599,0009,449,0009,227,0009,627,00010,015,00010,171,00010,162,0009,031,0008,849,0008,917,0008,360,0008,109,0007,991,0008,335,0008,007,0008,144,0008,153,0007,421,0007,591,0007,514,0007,721,0007,615,0007,329,0007,079,0006,954,0006,848,0006,690,0006,613,0006,560,0006,413,0006,205,0006,134,0005,913,0006,010,0005,989,0006,150,0006,173,0005,818,0005,728,0005,665,0005,882,0006,089,0006,094,0006,047,0006,335,0006,425,0006,526,0006,832,0007,062,0006,957,0007,096,0006,824,0007,067,0007,307,0007,363,0007,262,0006,820,0007,043,0007,830,0008,479,0008,486,0008,298,0008,316,0008,161,0007,420,0007,453,0007,297,0007,269,0007,453,0006,985,0007,262,0007,355,0006,985,0008,083,0009,177,0007,537,0007,556,0007,536,00010,058,0007,024,5209,581,7686,597,000000000000000000000000000000000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,097,000
1,102,000
9,698,000
9,713,000
9,884,000
9,906,000
9,903,000
9,870,000
9,874,000
9,855,000
9,887,000
9,893,000
9,889,000
9,866,000
9,846,000
9,878,000
9,871,000
9,890,000
9,877,000
9,874,000
9,862,000
9,871,000
9,887,000
9,898,000
9,898,000
9,881,000
9,958,000
9,943,000
9,981,000
11,601,000
11,560,000
11,368,000
11,550,000
11,387,000
11,467,000
11,430,000
11,868,000
11,988,000
11,848,000
11,806,000
11,658,000
11,688,000
11,774,000
11,841,000
11,825,000
11,834,000
11,717,000
11,729,000
11,707,000
11,674,000
11,668,000
11,595,000
11,668,000
11,569,000
11,645,000
11,711,000
11,845,000
11,765,000
11,798,000
20,081,000
19,997,000
19,963,000
19,821,000
19,707,000
19,820,000
20,001,000
19,960,000
19,939,000
20,048,000
20,048,00019,939,00019,960,00020,001,00019,820,00019,707,00019,821,00019,963,00019,997,00020,081,00011,798,00011,765,00011,845,00011,711,00011,645,00011,569,00011,668,00011,595,00011,668,00011,674,00011,707,00011,729,00011,717,00011,834,00011,825,00011,841,00011,774,00011,688,00011,658,00011,806,00011,848,00011,988,00011,868,00011,430,00011,467,00011,387,00011,550,00011,368,00011,560,00011,601,0009,981,0009,943,0009,958,0009,881,0009,898,0009,898,0009,887,0009,871,0009,862,0009,874,0009,877,0009,890,0009,871,0009,878,0009,846,0009,866,0009,889,0009,893,0009,887,0009,855,0009,874,0009,870,0009,903,0009,906,0009,884,0009,713,0009,698,0001,102,0001,097,0000000000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
827,000
1,075,000
1,082,000
1,089,000
1,174,000
1,246,000
1,234,000
978,000
1,606,000
1,435,000
1,336,000
1,512,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,512,0001,336,0001,435,0001,606,000978,0001,234,0001,246,0001,174,0001,089,0001,082,0001,075,000827,000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,807,000
0
2,870,978
0
2,884,000
2,910,000
4,762,000
2,907,000
2,826,000
2,712,000
2,696,000
2,763,000
2,712,000
4,204,000
4,609,000
4,710,000
3,107,000
3,345,000
11,723,000
11,682,000
11,467,000
13,778,000
13,638,000
13,223,000
12,323,000
12,040,000
12,098,000
12,230,000
12,226,000
13,040,000
12,832,000
12,945,000
12,158,000
12,232,000
12,072,000
11,661,000
10,980,000
11,027,000
13,609,000
16,677,000
16,448,000
16,051,000
16,391,000
17,256,000
16,047,000
21,532,000
21,150,000
20,351,000
20,981,000
20,319,000
20,486,000
19,997,000
22,646,000
29,627,000
29,438,000
28,507,000
27,586,000
27,386,000
27,465,000
27,124,000
26,188,000
25,850,000
24,887,000
24,418,000
21,959,000
22,852,000
22,257,000
21,454,000
20,833,000
19,718,000
19,728,000
20,613,000
20,947,000
20,347,000
20,006,000
44,104,000
42,387,000
41,265,000
39,900,000
39,585,000
39,307,000
39,291,000
38,326,000
37,687,000
38,089,000
38,089,00037,687,00038,326,00039,291,00039,307,00039,585,00039,900,00041,265,00042,387,00044,104,00020,006,00020,347,00020,947,00020,613,00019,728,00019,718,00020,833,00021,454,00022,257,00022,852,00021,959,00024,418,00024,887,00025,850,00026,188,00027,124,00027,465,00027,386,00027,586,00028,507,00029,438,00029,627,00022,646,00019,997,00020,486,00020,319,00020,981,00020,351,00021,150,00021,532,00016,047,00017,256,00016,391,00016,051,00016,448,00016,677,00013,609,00011,027,00010,980,00011,661,00012,072,00012,232,00012,158,00012,945,00012,832,00013,040,00012,226,00012,230,00012,098,00012,040,00012,323,00013,223,00013,638,00013,778,00011,467,00011,682,00011,723,0003,345,0003,107,0004,710,0004,609,0004,204,0002,712,0002,763,0002,696,0002,712,0002,826,0002,907,0004,762,0002,910,0002,884,00002,870,97802,807,000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,163,536
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,467,000
3,428,000
3,577,000
3,487,000
3,520,000
3,531,000
3,363,000
2,995,000
3,121,000
3,166,000
2,994,000
3,466,000
3,591,000
3,899,000
4,047,000
4,284,000
4,170,000
4,412,000
4,598,000
5,302,000
5,146,000
5,134,000
4,340,000
4,172,000
4,296,000
4,651,000
4,969,000
0
04,969,0004,651,0004,296,0004,172,0004,340,0005,134,0005,146,0005,302,0004,598,0004,412,0004,170,0004,284,0004,047,0003,899,0003,591,0003,466,0002,994,0003,166,0003,121,0002,995,0003,363,0003,531,0003,520,0003,487,0003,577,0003,428,0002,467,000000000000000000000000000000000000000000000000000000000019,163,5360000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,350,000
10,358,046
9,415,161
9,489,000
10,316,000
11,370,000
11,540,000
9,552,000
11,097,000
11,149,000
11,314,000
11,158,000
11,149,000
14,516,000
13,450,000
13,339,000
14,516,000
15,543,000
32,633,000
31,208,000
33,042,000
33,591,000
34,107,000
31,972,000
30,724,000
30,986,000
32,258,000
32,346,000
34,099,000
33,187,000
32,382,000
34,078,000
32,717,000
31,987,000
29,591,000
28,422,000
29,358,000
29,042,000
29,150,000
30,187,000
29,582,000
29,841,000
30,575,000
30,674,000
32,646,000
37,913,000
36,487,000
35,698,000
38,949,000
36,745,000
36,870,000
36,750,000
41,615,000
47,681,000
49,029,000
48,310,000
45,857,000
46,180,000
49,707,000
49,140,000
46,712,000
48,708,000
47,072,000
47,906,000
46,607,000
49,026,000
46,818,000
45,237,000
46,781,000
44,995,000
46,271,000
50,494,000
51,091,000
50,480,000
57,948,000
67,309,000
66,076,000
63,914,000
60,628,000
59,031,000
59,425,000
60,876,000
59,127,000
58,865,000
61,953,000
61,953,00058,865,00059,127,00060,876,00059,425,00059,031,00060,628,00063,914,00066,076,00067,309,00057,948,00050,480,00051,091,00050,494,00046,271,00044,995,00046,781,00045,237,00046,818,00049,026,00046,607,00047,906,00047,072,00048,708,00046,712,00049,140,00049,707,00046,180,00045,857,00048,310,00049,029,00047,681,00041,615,00036,750,00036,870,00036,745,00038,949,00035,698,00036,487,00037,913,00032,646,00030,674,00030,575,00029,841,00029,582,00030,187,00029,150,00029,042,00029,358,00028,422,00029,591,00031,987,00032,717,00034,078,00032,382,00033,187,00034,099,00032,346,00032,258,00030,986,00030,724,00031,972,00034,107,00033,591,00033,042,00031,208,00032,633,00015,543,00014,516,00013,339,00013,450,00014,516,00011,149,00011,158,00011,314,00011,149,00011,097,0009,552,00011,540,00011,370,00010,316,0009,489,0009,415,16110,358,04610,350,000000000000000000000000000000000000000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,215,000
8,159,428
7,121,790
7,095,000
7,695,000
7,747,000
6,957,000
6,760,000
7,782,000
6,839,000
6,797,000
6,741,000
6,839,000
9,447,000
8,405,000
8,088,000
9,447,000
10,349,000
24,933,000
15,528,000
15,187,000
15,682,000
15,991,000
14,456,000
13,320,000
14,049,000
15,143,000
15,116,000
17,640,000
16,994,000
16,304,000
16,852,000
16,787,000
16,016,000
13,838,000
14,657,000
15,752,000
15,800,000
14,801,000
14,128,000
13,903,000
13,862,000
15,197,000
14,675,000
16,051,000
17,513,000
16,322,000
15,824,000
17,330,000
15,758,000
16,150,000
16,036,000
14,869,000
15,932,000
14,335,000
15,382,000
15,256,000
15,429,000
15,657,000
14,463,000
16,383,000
18,164,000
17,201,000
15,248,000
16,292,000
18,256,000
16,034,000
14,776,000
18,117,000
17,043,000
18,183,000
18,942,000
20,307,000
21,513,000
22,222,000
23,649,000
22,594,000
22,740,000
21,815,000
24,850,000
26,293,000
24,860,000
26,375,000
28,588,000
30,542,000
30,542,00028,588,00026,375,00024,860,00026,293,00024,850,00021,815,00022,740,00022,594,00023,649,00022,222,00021,513,00020,307,00018,942,00018,183,00017,043,00018,117,00014,776,00016,034,00018,256,00016,292,00015,248,00017,201,00018,164,00016,383,00014,463,00015,657,00015,429,00015,256,00015,382,00014,335,00015,932,00014,869,00016,036,00016,150,00015,758,00017,330,00015,824,00016,322,00017,513,00016,051,00014,675,00015,197,00013,862,00013,903,00014,128,00014,801,00015,800,00015,752,00014,657,00013,838,00016,016,00016,787,00016,852,00016,304,00016,994,00017,640,00015,116,00015,143,00014,049,00013,320,00014,456,00015,991,00015,682,00015,187,00015,528,00024,933,00010,349,0009,447,0008,088,0008,405,0009,447,0006,839,0006,741,0006,797,0006,839,0007,782,0006,760,0006,957,0007,747,0007,695,0007,095,0007,121,7908,159,4288,215,000000000000000000000000000000000000000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
516,000
0
55,153
0
152,000
72,000
102,000
170,000
142,000
90,000
150,000
122,000
90,000
136,000
85,000
113,000
136,000
59,000
14,342,000
5,403,000
4,280,000
3,886,000
3,841,000
2,546,000
993,000
1,628,000
1,498,000
980,000
1,926,000
1,277,000
1,275,000
1,376,000
125,000
435,000
372,000
2,055,000
1,990,000
2,006,000
2,008,000
1,566,000
901,000
889,000
1,880,000
1,709,000
1,788,000
2,787,000
2,500,000
2,399,000
2,446,000
2,299,000
2,705,000
2,671,000
916,000
2,168,000
1,060,000
2,939,000
2,307,000
2,839,000
2,933,000
941,000
2,247,000
4,170,000
4,215,000
2,491,000
1,754,000
3,719,000
1,835,000
577,000
2,010,000
2,470,000
4,132,000
3,585,000
2,386,000
2,258,000
2,894,000
2,973,000
1,893,000
2,294,000
2,382,000
5,618,000
5,542,000
3,857,000
4,787,000
5,607,000
5,400,000
5,400,0005,607,0004,787,0003,857,0005,542,0005,618,0002,382,0002,294,0001,893,0002,973,0002,894,0002,258,0002,386,0003,585,0004,132,0002,470,0002,010,000577,0001,835,0003,719,0001,754,0002,491,0004,215,0004,170,0002,247,000941,0002,933,0002,839,0002,307,0002,939,0001,060,0002,168,000916,0002,671,0002,705,0002,299,0002,446,0002,399,0002,500,0002,787,0001,788,0001,709,0001,880,000889,000901,0001,566,0002,008,0002,006,0001,990,0002,055,000372,000435,000125,0001,376,0001,275,0001,277,0001,926,000980,0001,498,0001,628,000993,0002,546,0003,841,0003,886,0004,280,0005,403,00014,342,00059,000136,000113,00085,000136,00090,000122,000150,00090,000142,000170,000102,00072,000152,000055,1530516,000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,510,000
19,734,000
10,000
1,421,000
1,434,000
1,420,000
1,432,000
1,026,000
3,544,000
1,629,000
228,000
1,822,000
2,289,000
3,958,000
3,402,000
2,194,000
2,042,000
2,696,000
2,744,000
1,660,000
2,069,000
2,162,000
5,408,000
5,314,000
3,625,000
4,556,000
5,372,000
5,129,000
5,129,0005,372,0004,556,0003,625,0005,314,0005,408,0002,162,0002,069,0001,660,0002,744,0002,696,0002,042,0002,194,0003,402,0003,958,0002,289,0001,822,000228,0001,629,0003,544,0001,026,0001,432,0001,420,0001,434,0001,421,00010,00019,734,00017,510,000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,171,000
0
0
0
3,086,000
7,675,000
0
6,590,000
3,125,000
5,466,000
5,496,000
5,404,000
3,161,000
6,334,000
6,572,000
5,780,000
3,482,000
6,913,000
7,025,000
6,632,000
3,497,000
7,194,000
7,409,000
6,939,000
3,903,000
7,150,000
7,366,000
7,385,000
8,687,000
8,507,000
7,362,000
7,796,000
2,580,000
8,672,000
8,513,000
8,028,000
2,155,000
8,945,000
8,972,000
8,629,000
2,680,000
9,465,000
9,642,000
9,242,000
2,499,000
10,626,000
10,304,000
10,149,000
3,492,000
10,510,000
10,659,000
10,593,000
3,469,000
11,174,000
10,259,000
9,961,000
2,990,000
9,899,000
10,072,000
10,832,000
3,611,000
11,481,000
10,913,000
10,992,000
1,720,000
13,102,000
12,637,000
12,538,000
1,774,000
12,633,000
12,028,000
13,406,000
2,350,000
17,370,000
17,729,000
18,663,000
18,938,000
17,864,000
17,821,000
17,694,000
19,040,000
19,210,000
19,738,000
20,542,000
3,267,000
3,267,00020,542,00019,738,00019,210,00019,040,00017,694,00017,821,00017,864,00018,938,00018,663,00017,729,00017,370,0002,350,00013,406,00012,028,00012,633,0001,774,00012,538,00012,637,00013,102,0001,720,00010,992,00010,913,00011,481,0003,611,00010,832,00010,072,0009,899,0002,990,0009,961,00010,259,00011,174,0003,469,00010,593,00010,659,00010,510,0003,492,00010,149,00010,304,00010,626,0002,499,0009,242,0009,642,0009,465,0002,680,0008,629,0008,972,0008,945,0002,155,0008,028,0008,513,0008,672,0002,580,0007,796,0007,362,0008,507,0008,687,0007,385,0007,366,0007,150,0003,903,0006,939,0007,409,0007,194,0003,497,0006,632,0007,025,0006,913,0003,482,0005,780,0006,572,0006,334,0003,161,0005,404,0005,496,0005,466,0003,125,0006,590,00007,675,0003,086,0000003,171,000000000000000000000000000000000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,528,000
8,159,428
7,066,637
7,095,000
4,457,000
0
6,855,000
0
4,515,000
1,283,000
1,151,000
1,215,000
3,588,000
2,977,000
1,748,000
2,195,000
5,829,000
3,377,000
3,566,000
3,493,000
7,410,000
4,602,000
4,741,000
4,971,000
8,424,000
5,271,000
6,279,000
6,751,000
7,027,000
7,210,000
7,667,000
7,680,000
14,082,000
6,909,000
4,953,000
4,574,000
11,607,000
4,849,000
3,821,000
3,933,000
10,322,000
3,508,000
3,675,000
3,724,000
11,764,000
4,100,000
3,518,000
3,276,000
11,392,000
2,949,000
2,786,000
2,772,000
10,484,000
2,590,000
3,016,000
2,482,000
9,959,000
2,691,000
2,652,000
2,690,000
10,525,000
2,513,000
2,073,000
1,765,000
12,818,000
1,435,000
1,562,000
1,661,000
14,333,000
1,940,000
2,023,000
1,951,000
15,571,000
1,885,000
1,599,000
1,026,000
847,000
2,582,000
1,612,000
1,538,000
1,711,000
1,793,000
1,850,000
2,439,000
21,875,000
21,875,0002,439,0001,850,0001,793,0001,711,0001,538,0001,612,0002,582,000847,0001,026,0001,599,0001,885,00015,571,0001,951,0002,023,0001,940,00014,333,0001,661,0001,562,0001,435,00012,818,0001,765,0002,073,0002,513,00010,525,0002,690,0002,652,0002,691,0009,959,0002,482,0003,016,0002,590,00010,484,0002,772,0002,786,0002,949,00011,392,0003,276,0003,518,0004,100,00011,764,0003,724,0003,675,0003,508,00010,322,0003,933,0003,821,0004,849,00011,607,0004,574,0004,953,0006,909,00014,082,0007,680,0007,667,0007,210,0007,027,0006,751,0006,279,0005,271,0008,424,0004,971,0004,741,0004,602,0007,410,0003,493,0003,566,0003,377,0005,829,0002,195,0001,748,0002,977,0003,588,0001,215,0001,151,0001,283,0004,515,00006,855,00004,457,0007,095,0007,066,6378,159,4284,528,000000000000000000000000000000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,135,000
2,198,618
2,293,372
2,394,000
2,621,000
3,623,000
4,583,000
2,792,000
3,315,000
4,310,000
4,517,000
4,417,000
4,310,000
5,069,000
5,045,000
5,251,000
5,069,000
5,194,000
7,700,000
15,680,000
17,855,000
17,909,000
18,116,000
17,516,000
17,404,000
16,937,000
17,115,000
17,230,000
16,459,000
16,193,000
16,078,000
17,226,000
15,930,000
15,971,000
15,753,000
13,765,000
13,606,000
13,242,000
14,349,000
16,059,000
15,679,000
15,979,000
15,378,000
15,999,000
16,595,000
20,400,000
20,165,000
19,874,000
21,619,000
20,987,000
20,720,000
20,714,000
26,746,000
31,749,000
34,694,000
32,928,000
30,601,000
30,751,000
34,050,000
34,677,000
30,329,000
30,544,000
29,871,000
32,658,000
30,315,000
30,770,000
30,784,000
30,461,000
28,664,000
27,952,000
28,088,000
31,552,000
30,784,000
28,967,000
35,726,000
43,660,000
43,482,000
41,174,000
38,813,000
34,181,000
33,132,000
36,016,000
32,752,000
30,277,000
31,411,000
31,411,00030,277,00032,752,00036,016,00033,132,00034,181,00038,813,00041,174,00043,482,00043,660,00035,726,00028,967,00030,784,00031,552,00028,088,00027,952,00028,664,00030,461,00030,784,00030,770,00030,315,00032,658,00029,871,00030,544,00030,329,00034,677,00034,050,00030,751,00030,601,00032,928,00034,694,00031,749,00026,746,00020,714,00020,720,00020,987,00021,619,00019,874,00020,165,00020,400,00016,595,00015,999,00015,378,00015,979,00015,679,00016,059,00014,349,00013,242,00013,606,00013,765,00015,753,00015,971,00015,930,00017,226,00016,078,00016,193,00016,459,00017,230,00017,115,00016,937,00017,404,00017,516,00018,116,00017,909,00017,855,00015,680,0007,700,0005,194,0005,069,0005,251,0005,045,0005,069,0004,310,0004,417,0004,517,0004,310,0003,315,0002,792,0004,583,0003,623,0002,621,0002,394,0002,293,3722,198,6182,135,000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,994,000
17,874,000
24,601,000
28,939,000
28,888,000
0
0
0
0
0
0
0
0
0000000028,888,00028,939,00024,601,00017,874,00017,994,000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,081,000
17,255,000
17,763,000
14,765,000
14,850,000
14,415,000
14,234,000
11,114,000
11,062,000
10,856,000
10,753,000
10,283,000
9,476,000
10,133,000
10,527,000
10,491,000
9,630,000
9,636,000
13,203,000
13,011,000
11,582,000
10,735,000
9,444,000
8,499,000
8,237,000
7,701,000
7,233,000
0
07,233,0007,701,0008,237,0008,499,0009,444,00010,735,00011,582,00013,011,00013,203,0009,636,0009,630,00010,491,00010,527,00010,133,0009,476,00010,283,00010,753,00010,856,00011,062,00011,114,00014,234,00014,415,00014,850,00014,765,00017,763,00017,255,00016,081,000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,172,000
12,174,035
12,731,379
13,565,000
13,178,000
12,319,000
12,707,000
13,332,000
14,418,000
13,597,000
13,477,000
13,275,000
13,597,000
15,304,000
14,910,000
14,683,000
15,304,000
13,907,000
14,847,000
14,614,000
14,778,000
14,720,000
15,974,000
16,105,000
15,912,000
15,383,000
17,796,000
19,394,000
20,660,000
20,727,000
22,091,000
22,125,000
23,213,000
22,349,000
23,606,000
23,931,000
23,246,000
21,516,000
22,026,000
22,038,000
23,737,000
22,292,000
23,216,000
23,248,000
23,224,000
21,454,000
22,029,000
20,445,000
19,627,000
16,936,000
18,279,000
17,349,000
18,490,000
14,741,000
13,530,000
13,072,000
14,854,000
12,989,000
13,653,000
13,725,000
14,960,000
12,915,000
12,645,000
11,936,000
12,468,000
10,483,000
13,548,000
12,164,000
13,127,000
10,778,000
12,237,000
12,195,000
15,622,000
14,430,000
15,676,000
39,744,000
39,268,000
36,340,000
35,932,000
35,134,000
37,037,000
35,789,000
37,392,000
37,197,000
39,143,000
39,143,00037,197,00037,392,00035,789,00037,037,00035,134,00035,932,00036,340,00039,268,00039,744,00015,676,00014,430,00015,622,00012,195,00012,237,00010,778,00013,127,00012,164,00013,548,00010,483,00012,468,00011,936,00012,645,00012,915,00014,960,00013,725,00013,653,00012,989,00014,854,00013,072,00013,530,00014,741,00018,490,00017,349,00018,279,00016,936,00019,627,00020,445,00022,029,00021,454,00023,224,00023,248,00023,216,00022,292,00023,737,00022,038,00022,026,00021,516,00023,246,00023,931,00023,606,00022,349,00023,213,00022,125,00022,091,00020,727,00020,660,00019,394,00017,796,00015,383,00015,912,00016,105,00015,974,00014,720,00014,778,00014,614,00014,847,00013,907,00015,304,00014,683,00014,910,00015,304,00013,597,00013,275,00013,477,00013,597,00014,418,00013,332,00012,707,00012,319,00013,178,00013,565,00012,731,37912,174,03511,172,000000000000000000000000000000000000000000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
429,000
0
0
0
423,000
420,000
419,000
415,000
411,000
395,000
404,000
399,000
395,000
383,000
392,000
388,000
383,000
378,000
374,000
369,000
364,000
364,000
363,000
362,000
362,000
362,000
362,000
363,000
363,000
362,000
360,000
356,000
352,000
346,000
341,000
332,000
323,000
318,000
315,000
312,000
312,000
313,000
313,000
314,000
315,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
316,000
317,000
317,000
317,000
317,000
317,000
317,000
328,000
328,000
328,000
328,000
328,000
328,000
328,000
328,000
328,000
387,000
387,000
387,000
387,000
387,000
387,000
387,000
387,000
387,000
388,000
388,000387,000387,000387,000387,000387,000387,000387,000387,000387,000328,000328,000328,000328,000328,000328,000328,000328,000328,000317,000317,000317,000317,000317,000317,000316,000316,000316,000316,000316,000316,000316,000316,000316,000316,000316,000316,000316,000316,000316,000315,000314,000313,000313,000312,000312,000315,000318,000323,000332,000341,000346,000352,000356,000360,000362,000363,000363,000362,000362,000362,000362,000363,000364,000364,000369,000374,000378,000383,000388,000392,000383,000395,000399,000404,000395,000411,000415,000419,000420,000423,000000429,000000000000000000000000000000000000000000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,941,000
7,946,000
7,950,000
7,952,000
7,971,000
7,976,000
7,980,000
35,118,000
35,126,000
0
0
0
0
0
0
0
0
0000000035,126,00035,118,0007,980,0007,976,0007,971,0007,952,0007,950,0007,946,0007,941,00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,292,000
0
0
0
2,306,000
2,343,000
2,396,000
2,473,000
2,401,000
2,523,000
2,476,000
2,504,000
2,523,000
3,573,000
3,284,000
3,476,000
3,573,000
3,588,000
3,710,000
3,735,000
3,790,000
3,771,000
3,810,000
3,920,000
3,978,000
3,999,000
3,997,000
4,043,000
4,099,000
4,228,000
4,311,000
4,536,000
4,589,000
4,671,000
4,925,000
4,985,000
5,029,000
5,172,000
5,299,000
5,392,000
5,464,000
5,611,000
5,719,000
5,734,000
5,949,000
6,146,000
6,209,000
6,236,000
6,282,000
6,315,000
6,314,000
6,326,000
6,340,000
6,350,000
6,356,000
6,375,000
6,398,000
6,410,000
6,407,000
6,408,000
6,422,000
6,434,000
6,449,000
6,457,000
6,468,000
6,484,000
9,955,000
9,971,000
9,987,000
10,002,000
9,996,000
9,991,000
9,995,000
10,013,000
10,013,000
37,157,000
37,171,000
37,181,000
37,202,000
37,218,000
37,224,000
37,227,000
37,239,000
37,244,000
37,253,000
37,253,00037,244,00037,239,00037,227,00037,224,00037,218,00037,202,00037,181,00037,171,00037,157,00010,013,00010,013,0009,995,0009,991,0009,996,00010,002,0009,987,0009,971,0009,955,0006,484,0006,468,0006,457,0006,449,0006,434,0006,422,0006,408,0006,407,0006,410,0006,398,0006,375,0006,356,0006,350,0006,340,0006,326,0006,314,0006,315,0006,282,0006,236,0006,209,0006,146,0005,949,0005,734,0005,719,0005,611,0005,464,0005,392,0005,299,0005,172,0005,029,0004,985,0004,925,0004,671,0004,589,0004,536,0004,311,0004,228,0004,099,0004,043,0003,997,0003,999,0003,978,0003,920,0003,810,0003,771,0003,790,0003,735,0003,710,0003,588,0003,573,0003,476,0003,284,0003,573,0002,523,0002,504,0002,476,0002,523,0002,401,0002,473,0002,396,0002,343,0002,306,0000002,292,000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue45,811,000
Cost of Revenue-8,268,000
Gross Profit37,543,00037,543,000
 
Operating Income (+$)
Gross Profit37,543,000
Operating Expense-28,821,000
Operating Income8,193,0008,722,000
 
Operating Expense (+$)
Research Development10,935,000
Selling General Administrative18,222,000
Selling And Marketing Expenses18,222,000
Operating Expense28,821,00047,379,000
 
Net Interest Income (+$)
Interest Income301,000
Interest Expense-1,589,000
Other Finance Cost-0
Net Interest Income-1,288,000
 
Pretax Income (+$)
Operating Income8,193,000
Net Interest Income-1,288,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)6,899,0009,487,000
EBIT - interestExpense = 7,388,000
6,893,000
7,544,000
Interest Expense1,589,000
Earnings Before Interest and Taxes (EBIT)8,977,0008,488,000
Earnings Before Interest and Taxes (EBITDA)13,911,000
 
After tax Income (+$)
Income Before Tax6,899,000
Tax Provision-938,000
Net Income From Continuing Ops5,961,0005,961,000
Net Income5,955,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses37,089,000
Total Other Income/Expenses Net-1,294,0001,288,000
 

Technical Analysis of Astrazeneca
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Astrazeneca. The general trend of Astrazeneca is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Astrazeneca's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AstraZeneca PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1,491 < 1,513 < 1,521.

The bearish price targets are: 1,428 > 1,417 > 1,414.

Tweet this
AstraZeneca PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AstraZeneca PLC. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AstraZeneca PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AstraZeneca PLC. The current macd is 21.76.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Astrazeneca price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Astrazeneca. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Astrazeneca price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
AstraZeneca PLC Daily Moving Average Convergence/Divergence (MACD) ChartAstraZeneca PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AstraZeneca PLC. The current adx is 20.61.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Astrazeneca shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
AstraZeneca PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AstraZeneca PLC. The current sar is 1,336.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
AstraZeneca PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AstraZeneca PLC. The current rsi is 72.22. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
AstraZeneca PLC Daily Relative Strength Index (RSI) ChartAstraZeneca PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AstraZeneca PLC. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Astrazeneca price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
AstraZeneca PLC Daily Stochastic Oscillator ChartAstraZeneca PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AstraZeneca PLC. The current cci is 220.91.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
AstraZeneca PLC Daily Commodity Channel Index (CCI) ChartAstraZeneca PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AstraZeneca PLC. The current cmo is 59.76.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
AstraZeneca PLC Daily Chande Momentum Oscillator (CMO) ChartAstraZeneca PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AstraZeneca PLC. The current willr is -8.37004405.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
AstraZeneca PLC Daily Williams %R ChartAstraZeneca PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of AstraZeneca PLC.

AstraZeneca PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AstraZeneca PLC. The current atr is 22.20.

AstraZeneca PLC Daily Average True Range (ATR) ChartAstraZeneca PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AstraZeneca PLC. The current obv is 5,295,446.

AstraZeneca PLC Daily On-Balance Volume (OBV) ChartAstraZeneca PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AstraZeneca PLC. The current mfi is 55.87.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
AstraZeneca PLC Daily Money Flow Index (MFI) ChartAstraZeneca PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AstraZeneca PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

AstraZeneca PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AstraZeneca PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5072.221
Ma 20Greater thanMa 501,378.525
Ma 50Greater thanMa 1001,358.280
Ma 100Greater thanMa 2001,350.907
OpenGreater thanClose1,450.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Astrazeneca with someone you think should read this too:
  • Are you bullish or bearish on Astrazeneca? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Astrazeneca? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AstraZeneca PLC

I send you an email if I find something interesting about AstraZeneca PLC.


Comments

How you think about this?

Leave a comment

Stay informed about AstraZeneca PLC.

Receive notifications about AstraZeneca PLC in your mailbox!